Covid-19 vaccine developer BioNTech attracts Temasek investment

By Aidan Gregory
29 Jun 2020

German biotechnology company BioNTech has raised $225m via a private placement led by Singaporean sovereign wealth fund Temasek, amid growing investor appetite for biotech investments due to the Covid-19 pandemic.

BioNTech is in the process of developing a vaccine for Covid-19. It expects the results of its first clinical trials on the treatment known as BNT162 in July. The company is also involved in the development of personalised vaccines against cancer.

The placement was split across a ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial